Oragenics Inc OGEN Stock Analysis
- NYSE American
- Stock
- Market closed · opens Monday 9:30 AM ET
$0.35 up $0.00, 0.06% at close Nov 6
Last close · Previous close $0.35
- Market cap
- At the Nov 6 close
- P/E ratio
- PausedOn last 12 months’ EPS
See the note under the price. - Diluted EPS
- PausedLast 12 months
See the note under the price. - Dividend yield
- NoneLast 12 months
Price chart
$0.35up $0.00, 0.04%Fri, Nov 6 session
Use the left and right arrow keys to move along the chart.
Price data
Trading
- Previous close$0.35Nov 5
- Volume8.82KNov 6 session
Shares traded on all US exchanges in the last completed session. Live intraday volume covers IEX only, so it is left out.
- Avg. volume21.00KLast 21 sessions
The average daily shares traded over the last 21 trading sessions, about one calendar month.
- 52-week range: $0.34 to $1.22; now $0.35
The lowest and highest trades over the past 52 weeks, adjusted for splits. The marker shows the latest price.
Member SIPC.Low CommissionsLearn More (opens in a new tab)Sponsored. Affiliate link: I may earn a commission. The inclusion of Interactive Brokers’ (IBKR) name, logo or weblink is present pursuant to an advertising arrangement only. IBKR is not a contributor, reviewer, provider or sponsor of content published on this site, and is not responsible for the accuracy of any products or services discussed.
Performance
Past performance, measured to the Nov 6 close. Total return includes reinvested dividends.Price change only, without dividends. Compared with the S&P 500, using SPY.
OGEN trailed the S&P 500 in all 7 periods.
| Period | OGEN and S&P 500 | vs S&P 500 |
|---|---|---|
| Short term | ||
| 1M | OGEN: down 28.0% S&P 500: down 5.6% | OGEN trailed the S&P 500 by 22.4 percentage points Trailed |
| 3M | OGEN: down 35.8% S&P 500: down 4.1% | OGEN trailed the S&P 500 by 31.7 percentage points Trailed |
| YTD | OGEN: down 55.4% S&P 500: up 8.7% | OGEN trailed the S&P 500 by 64.1 percentage points Trailed |
| 1Y | OGEN: down 68.7% S&P 500: up 10.9% | OGEN trailed the S&P 500 by 79.6 percentage points Trailed |
| Long term | ||
| 3Y | OGEN: down 99.7% S&P 500: up 75.0% −85.4% vs +20.5% a year | OGEN trailed the S&P 500 by 174.7 percentage points Trailed |
| 5Y | OGEN: down 100.0% S&P 500: up 67.8% −80.2% vs +10.9% a year | OGEN trailed the S&P 500 by 167.8 percentage points Trailed |
| 10Y | OGEN: down 100.0% S&P 500: up 313.1% −62.7% vs +15.2% a year | OGEN trailed the S&P 500 by 413.1 percentage points Trailed |
$10,000 invested in OGEN 10 years ago (Nov 4, 2016) would be worth about $1 at the close on , with dividends reinvested. The same amount in the S&P 500 would be worth about $41,313.
OGEN trailed the S&P 500 in all 7 periods.
| Period | OGEN and S&P 500 | vs S&P 500 |
|---|---|---|
| Short term | ||
| 1M | OGEN: down 28.0% S&P 500: down 5.6% | OGEN trailed the S&P 500 by 22.4 percentage points Trailed |
| 3M | OGEN: down 35.8% S&P 500: down 4.3% | OGEN trailed the S&P 500 by 31.5 percentage points Trailed |
| YTD | OGEN: down 55.4% S&P 500: up 7.8% | OGEN trailed the S&P 500 by 63.2 percentage points Trailed |
| 1Y | OGEN: down 68.7% S&P 500: up 9.7% | OGEN trailed the S&P 500 by 78.4 percentage points Trailed |
| Long term | ||
| 3Y | OGEN: down 99.7% S&P 500: up 68.8% −85.4% vs +19.1% a year | OGEN trailed the S&P 500 by 168.5 percentage points Trailed |
| 5Y | OGEN: down 100.0% S&P 500: up 56.9% −80.2% vs +9.4% a year | OGEN trailed the S&P 500 by 156.9 percentage points Trailed |
| 10Y | OGEN: down 100.0% S&P 500: up 252.6% −62.7% vs +13.4% a year | OGEN trailed the S&P 500 by 352.6 percentage points Trailed |
$10,000 invested in OGEN 10 years ago (Nov 4, 2016) would be worth about $1 at the close on , not counting dividends. The same amount in the S&P 500 would be worth about $35,257.
All-time high
$1,584,000.00
Closing high on . Now 100.0% below that record.
Split-adjusted daily closes since Feb 25, 2004.
Stock splits
4
Latest: 1-for-30 on . Share counts adjust after each split.
All 4 splits
- 1-for-30
- 1-for-60
- 1-for-10
- 1-for-20
Valuation
Financials
Reported results, not forecasts. From company filings via Tiingo; the latest report is Q2 FY26, the quarter ended Jun 30, 2026. “Last 12 months” means the four quarters from Jul 1, 2025 to Jun 30, 2026, and balance-sheet figures are as of Jun 30, 2026.
Revenue and net income
Last 12 months, with the change from the 12 months before
- Revenue
- $0.00
- Net income
- −$10.08M
- Diluted EPS
- PausedSee the note under the price.
Data table
| Period | Revenue | Net income | Diluted EPS |
|---|---|---|---|
| Q3 FY24 (Sep 30, 2024) | $0.00 | −$2.46M | Paused See the note under the price. |
| Q4 FY24 (Dec 31, 2024) | $0.00 | −$3.35M | Paused See the note under the price. |
| Q1 FY25 (Mar 31, 2025) | $0.00 | −$2.22M | Paused See the note under the price. |
| Q2 FY25 (Jun 30, 2025) | $0.00 | −$2.27M | Paused See the note under the price. |
| Q3 FY25 (Sep 30, 2025) | $0.00 | −$3.07M | Paused See the note under the price. |
| Q4 FY25 (Dec 31, 2025) | $0.00 | −$2.29M | Paused See the note under the price. |
| Q1 FY26 (Mar 31, 2026) | $0.00 | −$2.20M | Paused See the note under the price. |
| Q2 FY26 (Jun 30, 2026) | $0.00 | −$2.53M | Paused See the note under the price. |
| Period | Revenue | Net income | Diluted EPS |
|---|---|---|---|
| FY21 (Dec 31, 2021) | $86.99K | −$15.71M | Paused See the note under the price. |
| FY22 (Dec 31, 2022) | $131.52K | −$14.29M | Paused See the note under the price. |
| FY23 (Dec 31, 2023) | $37.65K | −$20.66M | Paused See the note under the price. |
| FY24 (Dec 31, 2024) | $0.00 | −$10.57M | Paused See the note under the price. |
| FY25 (Dec 31, 2025) | $0.00 | −$9.84M | Paused See the note under the price. |
Margins
- Gross —
- Operating —
- Net —
The percentages above the chart cover the last 12 months; the lines show each quarter. What margins tell you
Cash flow
- −$10.21MLast 12 months
Cash from operations minus capital spending: the cash left after the business maintains and grows its assets.
FCF = Operating cash flow − Capital spendingFree cash flow - Operating cash flow−$10.21MLast 12 months
- Capital spending$0.00Last 12 months
Shareholder returns
- $78.07KLast 12 months
Cash spent repurchasing shares, net of shares issued. Buybacks shrink the share count, so each remaining share owns more of the company.
- Dividends paid$0.00Last 12 months
- Total returned$0.00Last 12 months
Balance sheet
- $3.86MAs of Jun 30, 2026
Cash plus short- and long-term marketable securities on the Jun 30, 2026 balance sheet.
- Total debt$0.00As of Jun 30, 2026
- Net cash$3.86MAs of Jun 30, 2026
- Book value per sharePausedAs of Jun 30, 2026
See the note under the price. - 3.01As of Jun 30, 2026
Current assets divided by current liabilities on the Jun 30, 2026 balance sheet. Above 1 means short-term assets cover the bills due within a year.
Current ratio = Current assets ÷ Current liabilitiesCurrent ratio - 0.00As of Jun 30, 2026
Total debt divided by shareholders’ equity on the Jun 30, 2026 balance sheet: a measure of financial leverage.
D/E = Total debt ÷ Shareholders’ equityDebt-to-equity ratio
Financial strength
- −144.2%Last 12 months
Over the last 12 months, Oragenics lost money: its net loss was 144.2% of its shareholders’ equity (averaged over the last four quarter-ends). It describes the past year, not an expected return.
ROE = Net income (last 12 months) ÷ Average equityReturn on equity - −112.8%Last 12 months
Over the last 12 months, Oragenics’s net loss was 112.8% of its total assets (averaged over the last four quarter-ends).
ROA = Net income (last 12 months) ÷ Average total assets
About Oragenics Inc
Oragenics is a development-stage biotechnology company focused on nasal delivery of pharmaceutical medications in neurology and fighting infectious diseases, including drug candidates for treating mild traumatic brain injury (mTBI), also known as concussion, and for treating Niemann Pick Disease Type C (NPC), as well as proprietary powder formulation and an intranasal delivery device.
- Sector
- Healthcare
- Industry
- Biotechnology
- Headquarters
- Florida, USA
- SEC filings
- EDGAR (opens in a new tab)
- Exchange
- NYSE American
- Asset type
- Common stock
- Price history since
OGEN news
Explore more stocks
Prices are from the last refresh. Open any stock for its live dashboard.
Popular stocks
OGEN stock FAQ
What is OGEN stock’s price today?
Oragenics (OGEN) traded at $0.35 at the close on , unchanged from the previous close of $0.35. Over the past 52 weeks it has traded between $0.34 and $1.22.
If you invested $1,000 in OGEN 10 years ago, how much would you have now?
With dividends reinvested, $1,000 invested in OGEN on would be worth about $0 at the close on , a total return of −100.0%. The same $1,000 would be worth $0 if invested five years ago, $313 if invested one year ago, and $0 if invested 20 years ago. Past performance doesn’t predict future returns.
Does OGEN pay a dividend?
Oragenics hasn’t paid a dividend in the last twelve months.
What is OGEN’s 52-week high and low?
Over the past 52 weeks OGEN has traded as low as $0.34 and as high as $1.22. At $0.35 at the close on , it is 71.4% below that high and 1.5% above the low.
What is OGEN’s all-time high?
OGEN’s highest closing price was $1,584,000.00 on , adjusted for stock splits. At $0.35 at the close on , it is 100.0% below that record.
Has OGEN stock ever split?
Yes, four times: 1-for-20 on ; 1-for-10 on ; 1-for-60 on ; 1-for-30 on .
How has OGEN stock performed?
Including dividends and measured to the close on , OGEN has returned −55.4% so far this year and −68.7% over the past year, and −100.0% over five years (−80.2% a year). Over the same periods the S&P 500, measured by SPY, returned +8.7%, +10.9% and +67.8%. Past performance doesn’t predict future returns.
What sector and industry is Oragenics in?
Oragenics is in the Healthcare sector and the Biotechnology industry, and is headquartered in Florida, USA.
What exchange does OGEN trade on?
Oragenics trades on the NYSE American under the ticker symbol OGEN. Its price history on this dashboard begins on .
Member SIPC.Low CommissionsLearn More (opens in a new tab)Sponsored. Affiliate link: I may earn a commission. The inclusion of Interactive Brokers’ (IBKR) name, logo or weblink is present pursuant to an advertising arrangement only. IBKR is not a contributor, reviewer, provider or sponsor of content published on this site, and is not responsible for the accuracy of any products or services discussed.
About this data. Data sourced by Tiingo (opens in a new tab). The live price is Tiingo’s real-time price, based on IEX trades and quotes; intraday charts show IEX trades, and volume figures are consolidated totals for completed sessions. Prices are split-adjusted, and total returns assume dividends are reinvested. Financials come from company filings and can lag new reports. Times are Eastern.
This page is for education, not investment advice. Past performance doesn't predict future returns. Logos provided by Logo.dev (opens in a new tab).
The Interactive Brokers word and logo are trademarks of Interactive Brokers LLC (or its subsidiaries) in the US and/or elsewhere. All rights reserved.